Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

These findings suggest that CagriSema could represent a highly effective therapeutic option for both weight and glycaemic management in people with Type 2 diabetes. While the gastrointestinal side ...

Photo: REUTERS/Hollie Adams/File Photo Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Still, experts say CagriSema could become a powerful new tool in the global effort to address obesity. At UAB, Garvey holds the C. E. Butterworth, Jr., MD, Professorship in the Department of Nutrition ...

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO.

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo Nordisk's Wegovy. On Monday, Novo Nordisk terminated the partnership ...

Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation We’re cutting our fair value estimate after lowering our near-term Wegovy sales estimates.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker struggles to fend off rivals in the burgeoning weight-loss market it ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial results on Monday trading.